[1] TERRY S F.Obama's precision medicine initiative[J].Genetic Testing and Molecular Biomarkers, 2015, 19(3):113-114.
[2] MURRAY J F.Personalized medicine:been there, done that, always needs work![J].American Journal of Respiratory and Critical Care Medicine, 2012, 185(12):1251-1252.
[3] HUDSON T J, ANDERSON W, ARTEZ A, et al.International network of cancer genome projects[J].Nature, 2010, 464(7291):993-998.
[4] KWONG G A, GHOSH S.Synthetic biomarkers:a twenty-first century path to early cancer detection[J].Nature Reviews Cancer, 2021, 21(10):655-668.
[5] WU Y L, TSUBOI M, HE J, et al.Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J].The New England Journal of Medicine, 2020, 383(18):1711-1723.
[6] KOPETZ S, GROTHEY A, YAEGER R, et al.Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer[J].The New England Journal of Medicine, 2019, 381(17):1632-1643.
[7] MIZRAHI J D, SURANA R, VALLE J W, et al.Pancreatic cancer[J].Lancet(London, England), 2020, 395(10242):2008-2020.
[8] VALLE J W, KELLEY R K, NERVI B, et al.Biliary tract cancer[J].Lancet(London, England), 2021, 397(10272):428-444.
[9] RANGANATHAN P, CHINNASWAMY G, SENGAR M, et al.The International Collaboration for Research methods Development in Oncology(CReDO) workshops:shaping the future of global oncology research[J].The Lancet Oncology, 2021, 22(8):e369-e376.
[10] CHIN L, KHOZIN S.A digital highway for data fluidity and data equity in precision medicine[J].Biochimica et Biophysica Acta Reviews on Cancer, 2021, 1876(1):188575.
[11] ANNARATONE L, DE PALMA G, BONIZZI G, et al.Basic principles of biobanking:from biological samples to precision medicine for patients[J].Virchows Archiv:an International Journal of Pathology, 2021, 479(2):233-246.
[12] MEGGENDORFER M, JOBANPUTRA V, WRZESZCZYNSKI K O, et al.Analytical demands to use whole-genome sequencing in precision oncology[J].Seminars in Cancer Biology, 2021, 84:16-22.
[13] VITALE I, SHEMA E, LOI S, et al.Intratumoral heterogeneity in cancer progression and response to immunotherapy[J].Nature Medicine, 2021, 27(2):212-224.
[14] DUGGER S A, PLATT A, GOLDSTEIN D B.Drug development in the era of precision medicine[J].Nature Reviews Drug Discovery, 2018, 17(3):183-196.
[15] KERK S A, PAPAGIANNAKOPOULOS T, SHAH Y M, et al.CA.Metabolic networks in mutant KRAS-driven tumours:tissue specificities and the microenvironment[J].Nature Reviews Cancer, 2021, 21(8):510-525.
[16] HALLBERG B, PALMER R H.Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology[J].Nature Reviews Cancer, 2013, 13(10):685-700.
[17] PARK J J H, SIDEN E, ZORATTI M J, et al.Systematic review of basket trials, umbrella trials, and platform trials:a landscape analysis of master protocols[J].Trials, 2019, 20(1):572.
[18] BILLINGHAM L, MALOTTKI K, STEVEN N.Research methods to change clinical practice for patients with rare cancers[J].The Lancet Oncology, 2016, 17(2):e70-e80.
[19] MULLARD A.NCI-MATCH trial pushes cancer umbrella trial paradigm[J].Nature Reviews Drug Discovery, 2015, 14(8):513-515.
[20] LENGLINE E, PERON J, VANIER A, et al.Basket clinical trial design for targeted therapies for cancer:a French National Authority for Health statement for health technology assessment[J].The Lancet Oncology, 2021, 22(10):e430-e434.
[21] LOPEZ-CHAVEZ A, THOMAS A, RAJAN A, et al.Molecular profiling and targeted therapy for advanced thoracic malignancies:a biomarker-derived, multiarm, multihistology phase Ⅱ basket trial[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology, 2015, 33(9):1000-1007.
[22] TSIMBERIDOU A M, ISKANDER N G, HONG D S, et al.Personalized medicine in a phase Ⅰ clinical trials program:the MD Anderson Cancer Center initiative[J].Clinical Cancer Research:an Official Journal of the American Association for Cancer Research, 2012, 18(22):6373-6383.
[23] SCHWAEDER M, ZHAO M, LEE J J, et al.Impact of precision medicine in diverse cancers:a Meta-analysis of phase ii clinical trials[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology, 2015, 33(32):3817-3825.
[24] PRASAD V, FOJO T, BRADA M.Precision oncology:origins, optimism, and potential[J].The Lancet Oncology, 2016, 17(2):e81-86.
[25] MELO S A, LUECKE L B, KAHLERT C, et al.Glypican-1 identifies cancer exosomes and detects early pancreatic cancer[J].Nature, 2015, 523(7559):177-182.
[26] WANG X, HU L, YANG X, et al.Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy[J].Experimental and Therapeutic Medicine, 2021, 22(4):1140.
[27] MAYERS J R, WU C, CLISH C B, et al.Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development[J].Nature Medicine, 2014, 20(10):1193-1198.
[28] ZILL O A, GREENE C, SEBISANOVIC D, et al.Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas[J].Cancer Discovery, 2015, 5(10):1040-1048.
[29] GENTLES A J, NEWMAN A M, LIU C L, et al.The prognostic landscape of genes and infiltrating immune cells across human cancers[J].Nature Medicine, 2015, 21(8):938-945.
[30] ZHANG L, FARRELL, ZHOU H, et al.Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer[J].Gastroenterology, 2010, 138(3):949-957.
[31] WANG C F, SHI X J.Generation and application of patient-derived xenograft models in pancreatic cancer research[J].Chinese Medical Journal, 2019, 132(22):2729-2736.
[32] WADDELL N, PAJIC M, PATCH A M, et al.Whole genomes redefine the mutational landscape of pancreatic cancer[J].Nature, 2015, 518(7540):495-501.
[33] BAILEY P, CHANG D K, NONES K, et al.Genomic analyses identify molecular subtypes of pancreatic cancer[J].Nature, 2016, 531(7592):47-52.
[34] CHANTRILL L A, NAGRIAL A M, WATSON C, et al.Precision medicine for advanced pancreas cancer:the individualized molecular pancreatic cancer therapy(IMPaCT) trial[J].Clinical Cancer Research:an Official Journal of the American Association for Cancer Research, 2015, 21(9):2029-2037.
[35] REISS K A, MICK R, OHARA M H, et al.Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology, 2021, 39(22):2497-2505.
[36] GOLAN T, HAMMEL P, RENI M, et al.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J].The New England Journal of Medicine, 2019, 381(4):317-327.
[37] ALLEN M J, ZHANG A, BAVI P, et al.Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature[J/OL].Journal of Clinical Pathology, 2021.https://pubmed.ncbi.nlm.nih.gov/4583947/
[38] DOEBELE R C, DRILON A, PAZ-ARES L, et al.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours:integrated analysis of three phase 1-2 trials[J].The Lancet Oncology, 2020, 21(2):271-282.
[39] MIDDLETON G, PALMER D H, GREENHALF W, et al.Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma(ViP):a prospective, randomised, double-blind, multicentre phase 2 trial[J].The Lancet Oncology, 2017, 18(4):486-499.
[40] MOORE M J, GOLDSTEIN D, HAMM J, et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology, 2007, 25(15):1960-1966.
[41] ZHOU H, QIAN W, UCKUN F M, et al.IGF1 receptor targeted theranostic nanoparticles for targeted and image-guided therapy of pancreatic cancer[J].ACS Nano, 2015, 9(8):7976-7991.
[42] KINDLER H L, IOKA T, RICHEL D J, et al.Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma:a double-blind randomised phase 3 study[J].The Lancet Oncology, 2011, 12(3):256-262. |
